Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) Equity Income (2023 - 2025)

Rallybio (RLYB) has disclosed Equity Income for 3 consecutive years, with -$287000.0 as the latest value for Q2 2025.

  • Quarterly Equity Income rose 41.07% to -$287000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$874000.0 through Dec 2025, up 60.96% year-over-year, with the annual reading at -$874000.0 for FY2025, 60.96% up from the prior year.
  • Equity Income hit -$287000.0 in Q2 2025 for Rallybio, up from -$587000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$217000.0 in Q2 2023 to a low of -$685000.0 in Q1 2024.
  • Historically, Equity Income has averaged -$515400.0 across 3 years, with a median of -$575000.0 in 2023.
  • Biggest five-year swings in Equity Income: crashed 124.42% in 2024 and later surged 41.07% in 2025.
  • Year by year, Equity Income stood at -$613000.0 in 2023, then rose by 29.85% to -$430000.0 in 2024, then skyrocketed by 33.26% to -$287000.0 in 2025.
  • Business Quant data shows Equity Income for RLYB at -$287000.0 in Q2 2025, -$587000.0 in Q1 2025, and -$430000.0 in Q4 2024.